We are investigating the fairness of the proposed sale of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) (“DNB”) to Clearlake Capital for $9.15 per share in cash.
Notably, as detailed below, the sale price is below the price target for DNB of at least seven Wall Street analysts (source: TipRanks).
Additionally, the sale price is well below DNB’ 52-week high of $12.95 per share, and thus the deal appears highly opportunistic.
If you remain a DNB shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On March 24, 2025, DNB announced that it had agreed to be sold to Clearlake Capital for $9.15 per share in cash.
Notably, the sale price is below the price target for DNB of at least seven Wall Street analysts following DNB:
- Faiza Alwy of Deutsche Bank ($17.00 per share target)
- Surinder Thind of Jefferies ($15.00 per share target)
- Kyle Peterson of Needham ($14.00 per share target)
- Ashish Sabadra of RBC Capital ($12.00 per share target)
- George Tong of Goldman Sachs ($11.00 per share target)
- Manav Patnaik of Barclays ($11.00 per share target)
- Andrew Steinerman of J.P. Morgan ($10.00 per share target)
(source: TipRanks)
Additionally, the sale price is well below DNB’ 52-week high of $12.95 per share, and thus the deal appears highly opportunistic.
“We are investigating whether the DNB Board of Directors acted in the best interests of DNB shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to DNB shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”